Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Jerini
Evaluate
August 25, 2011
Shire loses with Dermagraft and wins with Firazyr
June 24, 2011
Adcom vote gives Firazyr new momentum
June 17, 2011
Event - Self administration key to Shire's Firazyr hopes
May 18, 2011
Shire finds its fourth way
March 02, 2011
Shire needs Firazyr to stand out in HAE crowd
September 17, 2010
EP Vantage Interview – Shire seeking a fourth way
February 19, 2009
Potential for a ViroPharma rebound
November 28, 2008
Companies desperate for a partner
August 19, 2008
Dyax looking strong ahead of second attempt in HAE race
August 07, 2008
Companies on the way to being 2008's winners and losers - European focus
July 16, 2008
ViroPharma takes gamble with Lev acquisition
Load More
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 15, 2023
Pharma’s Biggest Spenders 2022 Infographic
May 03, 2023
Gene Editing: Overhyped or Unstoppable Tide?
Editor's Picks
May 16, 2023
Heightened US antitrust fears rattle biopharma
May 11, 2023
2023’s biggest launches: the story so far
May 17, 2023
Viking’s Voyage is not over yet
May 09, 2023
Gene editing: overhyped or unstoppable tide?
May 16, 2023
A slow (and low) year for FDA approvals